Nkarta’s NKX019 Faces Delays in Autoimmune Disease Trials Despite Promise

Nkarta Therapeutics (NKTX) is developing NKX019, an experimental cell therapy designed to treat autoimmune diseases by depleting B cells. The company’s only drug candidate, NKX019, is currently in two clinical trials—Ntrust-1 and Ntrust-2—targeting conditions such as lupus nephritis, scleroderma, and myositis. Despite early promising signals, delays and financial pressures have cast uncertainty over its future.

NKX019 uses CAR-NK technology to target CD19, a protein found on B cells. The goal is to reset the immune system by removing these cells, potentially inducing remission in autoimmune disorders. Early studies have shown encouraging signs of B cell depletion in models, including non-Hodgkin lymphoma.

The company, however, faces significant challenges. Clinical data for NKX019 has been pushed back to the first half of 2026, later than the original timeline of late 2025. This delay adds to investor concerns, as NKTX’s market value reflects scepticism about its pipeline, despite holding over $313 million in cash and investments as of Q3 2025.

Nkarta has not disclosed the names of the broader research team behind NKX019, though individual trial sites list principal investigators like Dr. Michael R Bubb at the University of Florida. The company’s financial position remains strong for now, with an operational runway extending into 2029. Yet, competition in the cell therapy space and the high risk of failure in autoimmune disease treatments continue to weigh on its prospects.

NKTX’s future hinges on the success of NKX019, its sole drug in development. The delayed data readout and competitive pressures create hurdles, even as the company maintains a solid cash reserve. If clinical results prove positive, NKX019 could offer a new approach to treating autoimmune diseases by targeting B cells.